Thursday, April, 18, 2019 09:22:03

AbCellera to sign multi-target partnership deal with Novartis

AbCellera Biologics Inc., the antibody therapeutics developer based in Vancouver, has reportedly entered into a multi-year, multi-target partnership agreement with Novartis International AG, the Swiss multinational pharmaceutical company. Reportedly, the agreement entails the identification of antibodies for about ten therapeutic targets in the pipeline of …

GrapheneCA plans graphene production for cosmetics & pharma sectors

Nano Graphene Inc. (also known as GrapheneCA), a US-based supplier of graphene-based materials, has reportedly announced its plans to make graphene readily available for use in the cosmetics and pharmaceutical industries. Reportedly, GrapheneCA’s latest move helps in paving the path for the introduction & licensing …

Cognoa receives FDA breakthrough designation for its digital devices

These digital devices are the basis of Cognoa’s precision health platform. The FDA Breakthrough Device Program is envisioned to help patients in receiving timely access to advance technologies. Cognoa, Inc., the developer of AI-based personalized therapies and digital diagnostics, has reportedly announced that its first …